Adjuvant endocrine therapy for premenopausal women with breast cancer

Breast

Volumn 18, Issue SUPPL.3, 2009, Pages

  Puhalla, Shannon ^a,b   Brufsky, Adam ^b   Davidson, Nancy ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Estrogen receptor; GNRH agonists; Ovarian suppression; Premenopausal breast cancer; Tamoxifen

Indexed keywords

ANASTROZOLE; BUSERELIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2D6; DOXORUBICIN; ESTROGEN RECEPTOR; EXEMESTANE; FLUOROURACIL; GOSERELIN; LEUPRORELIN; MELPHALAN; METHOTREXATE; PROGESTERONE RECEPTOR; TAMOXIFEN; TAMOXIFEN CITRATE; TRIPTORELIN; VINCRISTINE; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER RECURRENCE; CANCER RELAPSE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; HORMONAL THERAPY; HUMAN; INDIVIDUALIZATION; MEDICAL SOCIETY; MEDLINE; MULTIPLE CYCLE TREATMENT; OVARIECTOMY; OVERALL SURVIVAL; PATIENT DECISION MAKING; PATIENT SELECTION; PHARMACOGENOMICS; PREMENOPAUSE; PRIORITY JOURNAL; RISK REDUCTION; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES;

EID: 71749102218     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9776(09)70286-3     Document Type: Article

References (66)

1. Clarke M.J. Ovarian ablation in breast cancer, 1896 to 1998: milestones along hierarchy of evidence from case report to Cochrane review. BMJ 317 (1998) 1246-1248
2. Nissen-Meyer R. Primary breast cancer: the effect of primary ovarian irradiation. Ann Oncol 2 5 (1991) 343-346
3. Leung S.F., Tsao S.Y., Teo P.M., Choi P.H., and Shiu W.C. Ovarian ablative failures by radiation: a comparison of two dose schedules. Br J Radiol 64 (1991) 537-538
4. Dees E.C., and Davidson N.E. Ovarian ablation as adjuvant therapy for breast cancer. Semin Oncol 28 4 (2001) 322-331
5. Beatson G.W. On the treatment of inoperable cases of carcinoma of the mamma: suggestions of a new method of treatment with illustrative cases. Lancet 2 (1896) 162-165
6. Davidson N.E. Ovarian ablation as treatment for young women with breast cancer. J Natl Cancer Inst Monogr 16 (1994) 95-99
7. Limonta P., Montaggnami Marelli M., and Moretti R.M. LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action. Expert Opin Invest Drugs 10 (2001) 709-720
8. Harvey H.A., Lipton A., Max D.T., Pearlman H.G., Diaz-Perches R., and de la Garza J. Medical castration produced by the GnRH analogue leuprolide to treat metastatic breast cancer. J Clin Oncol 3 8 (1985) 1068-1072
9. Taylor C.W., Green S., Dalton W.S., et al. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J Clin Oncol 16 (1998) 994-999
10. Boccardo F., Rubagotti A., Perrotta A., et al. Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric Italian study. Ann Oncol 5 (1994) 337-342
11. Systematic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339 (1992) 1-15 71-85.
12. Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet 348 9036 (1996) 1189-1196
13. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 (2005) 1687-1717
14. LHRH-agonists in Early Breast Cancer Overview group, Cuzick J., Ambroisine L., Davidson N., et al. Use of luteinising-hormone-releasing-hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 369 (2007) 1711-1723
15. Kaufmann M., Jonat W., Blamey R.W., et al. Survival analyses from the ZEBRA study: Gosereline (Zoladex) versus CMF in pre-menopausal women with node-positive breast cancer. Eur J Cancer 39 (2003) 1711-1717
16. Ejlertsen B., Mouridsen H.T., Jensen M.B., et al. Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer. J Clin Oncol 24 31 (2006) 4956-4962
17. Thomson C.S., Twelves C.J., Mallon E.A., and Leake R.E. Adjuvant ovarian ablation vs CMF chemotherapy in premenopausal breast cancer patients: trial update and impact of immunohistochemical assessment of ER status. Breast Edinburgh 11 5 (2002) 419-429
18. Schmid P., Untch M., Wallwiener D., et al. Cyclophosphamide, methotrexate, and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: Preliminary results of the TABLE study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate). Anticancer Res 22 (2002) 2325-2332
19. International Breast Cancer Study Group. Adjuvant therapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer. J Natl Cancer Inst 95 (2003) 1833-1846
20. Von Minckwitz G., Graf E., Geberth M., et al. CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor positive breast cancer in premenopausal patients: A randomised trial (GABG trial IV-A-93). Eur J Cancer 42 (2006) 1780-1788
21. Davidson N.E., O'Neill A.M., Vukov A.M., et al. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J Clin Oncol 23 25 (2005) 5973-5982
22. Kaufmann M., Graf E., Jonat W., et al. A randomised trial of goserelin versus control after adjuvant risk-adapted chemotherapy in premenopausal patients with primary breast cancer - GABG-IV B-93. Eur J Cancer 43 (2007) 2351-2358
23. Arriagada R., Le M.G., Spielmann M., et al. Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy. Ann Oncol 16 3 (2005) 389-396
24. De Placido S., De Laurentiis M., De Lena M., et al. Randomised facotrial trial of sequential doxorubicin and CMF vs. CMF and chemotherapy alone vs. chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer. Br J Cancer 92 (2005) 467-474
25. Baum M., Hackshaw A., Houghton J., et al. Adjuvant goserelin in pre-menopausal patietns with early breast cancer: Results from the ZIPP study. Eur J Cancer 42 (2006) 895-904
26. Thürlimann B., Price K.N., Gelber R.D., et al. Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93. Breast Cancer Res Treat 113 1 (2009) 137-144
27. Yarnold J.R., Bliss J.M., Earl D., et al. Ovarian ablation (OA) in pre-menopausal women with early breast cancer prescribed 5 years of tamoxifen (T) or T plus chemotherapy (CT) - results from the UK NCRI Adjuvant Breast Cancer (ABC) international trial of 2,144 patients. J Clin Oncol 22 (2004) abstract 535.
28. Boccardo F., Rubagotti A., Amoroso D., et al. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: Results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. J Clin Oncol 18 14 (2000) 2718-2727
29. Roche H., Kerbrat P., Bonneterre J., et al. Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial. Ann Oncol 17 8 (2006) 1221-1227
30. Roche H., Mihura J., de Lafontan B., et al. Castration and tamoxifen versus chemotherapy (FAC) for premenopausal, node and receptor positive breast cancer patients: A randomized trial witha7years median follow up. Proc Am Soc Clin Oncol 15 (1996) 117 (abstract 34).
31. Boccardo F., Rubagotti A., Amoroso D., et al. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (breast cancer adjuvant chemo-hormone therapy cooperative group) trial. Eur J Cancer 28 2-3 (1992) 673-680
32. Jakesz R., Hausmaninger H., Kubista E., et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer - Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol 20 24 (2002) 4621-4627
33. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet Oncol 351 (1998) 1451-1467
34. Fisher B., Costantino J., Redmond C., et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320 8 (1989) 479-484
35. Fisher B., Dignam J., Bryant J., et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88 21 (1996) 1529-1542
36. Breast Cancer Trials Committee, and Scottish Cancer Trials Office. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial: Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh. Lancet 330 8552 (1987) 171-175
37. Stewart H.J., Prescott R.J., and Forrest A. Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years. J Natl Cancer Inst 93 6 (2001) 456-462
38. Love R.R., Van Dinh N., Quy T.T., et al. Survival after adjuvant oophorectomy and tamoxifen in operable breast cancer in premenopausal women. J Clin Oncol 26 (2008) 253-257
39. Kaufmann M., Jonat W., Abel U., et al. Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer. J Clin Oncol 11 3 (1993) 454-460
40. International Breast Cancer Study Group. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph-node positive breast cancer: International Breast Cancer Study Group Trial 13-93. J Clin Oncol 24 (2006) 1332-1341
41. Andersson M., Kambry C., Jensen M.B., et al. Tamoxifen in high-risk premenopausal women with primary breast cancer receiving adjuvant chemotherapy: Report from the Danish Breast Cancer Co-operative Group DBCG 82B Trial. Eur J Cancer 35 (1999) 1659-1666
42. Fisher B., Redmond C., Brown A., et al. Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the NSABP trial. J Clin Oncol 4 (1986) 459-471
43. Morales L., Canney P., Dyczka J., et al. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: A randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group. Eur J Cancer 43 (2007) 331-340
44. Ingle J.N., Everson L.K., Wieand H.S., et al. Randomized trial to evaluate the addition of tamoxifen to cyclophosphamide, 5-fluorouracil, prednisone adjuvant therapy in premenopausal women with node-positive breast cancer. Cancer 63 (1989) 1257-1264
45. Tormey D.C., Gray R., Gilchrist K., et al. Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen with CMF for premenopausal breast cancer patients: An Eastern Cooperative Oncology Group Trial. Cancer 65 (1990) 200-206
46. De Placido S., De Laurentiis M., Carlomagno C., et al. Twenty-year results of the Naples GUN randomized trial: Predictive factors of adjuvant tamoxifen efficacy in early breast cancer. Clin Cancer Res 9 (2003) 1039-1046
47. Fisher B., Dignam J., Wolmark N., et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen-receptor positive breast cancer. J Natl Cancer Inst 89 (1997) 1673-1682
48. Klijn J.G., Blamey R.W., Boccardo F., Tominaga T., Duchateau L., and Sylvester R. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 19 2 (2001) 343-353
49. Klijn J.G., Beex L.V., Mauriac L., et al. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst 92 11 (2000) 903-911
50. Soreide J.A., Varhaug J.E., Fjosne H.E., et al. Adjuvant endocrine treatment (goserelin vs. tamoxifen) in pre-menopausal patients with operable node positive stage II breast cancer. A prospective randomized national multicenter study. Eur J Surg Oncol 28 (2002) 505-510
51. Belfiglio M., Valentini M., Pellegrini F., et al. Twelve-year mortality results of a randomized trial of 2 versus 5 years of adjuvant tamoxifen for postmenopausal early-stage breast carcinoma patients (SITAM 01). Cancer 104 11 (2005) 2334-2339
52. Delozier T., Spielmann M., Mace-Lesec'h J., et al. Tamoxifen adjuvant treatment duration in early breast cancer: initial results of a randomized study comparing short-term treatment with long-term treatment. J Clin Oncol 18 20 (2000) 3507-3512
53. Tormey D.C., Gray R., and Falkson H.C. Postchemotherapy adjuvant tamoxifen therapy beyond five years in lymph node-positive breast cancer. Eastern Cooperative Oncology Group. J Natl Cancer Inst 24 (1996) 1828-1833
54. Fisher B., Dignam J., Bryant J., et al. Five versus more than five years of tamoxifen for lymph-node negative breast cancer: Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 93 (2001) 684-690
55. Peto R., Davies C., and on behalf of the ATLAS collaboration. ATLAS (Adjuvant Tamoxifen, Longer against Shorter): International trial of 10 versus 5 years of adjuvant tamoxifen among 11,500 women. Breast Cancer Res Treat 106 (2007) abstract 48.
56. Gray R.G., Rea D.W., Handley K., et al. aTTom (adjuvant Tamoxifen - To offer more?): randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6,934 women with estrogen receptor-positive (ER+) or ER untested breast cancer - preliminary results. aTTom Collaborators. J Clin Oncol 26 (2008) abstr 513.
57. Forbes J.F., Cuzick J., Buzdar A., Howell A., et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncology 9 (2008) 45-53
58. Coombes R.C., Kilburn L.S., Snowdon C.F., Paridaens R., Coleman R.E., Jones S.E., et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369 9561 (2007) 559-570
59. Goss P.E., Ingle J.N., Pater J.L., et al. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol 26 12 (2008) 1948-1955
60. The Breast International Group 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353 26 (2005) 2747-2757
61. Forward D.P., Cheung K.L., Jackson L., and Robertson J.F. Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br J Cancer 90 3 (2004) 590-594
62. Gnant M., Mlineritsch B., Schippinger W., Luschin-Ebengreuth G., Postlberger S., Menzel C., et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360 7 (2009) 679-691
63. Goetz M.P., Rae J.M., Suman V.J., Safgren S.L., et al. Pharmacogenetics of tamoxifen biotransformation is assocaited with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23 (2005) 9312-9318
64. Stebbing J., Stearns V., and Davidson N.E. Role of CYP2D6 testing in selection of endocrine therapy for breast cancer. Pharmacogenomics 8 (2007) 1-3
65. Paik S., Shak S., Tang G., Kim C., Baker J., Cronin M., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351 27 (2004) 2817-2826
66. Dellapasqua S., Colleoni M., Gelber R.D., and Goldhirsch A. Adjuvant endocrine therapy for premenopausal women with early breast cancer. J Clin Oncol 23 8 (2005) 1736-1750